Check for updates

OPEN ACCESS

EDITED BY

Zhangbin Yu, The Second Clinical Medical College of Jinan University, First Affiliated Hospital of Southern University of Science and Technology, China

REVIEWED BY

Rubia Khalak, Albany Medical College, United States Suksham Jain, Government Medical College and Hospital, India

*CORRESPONDENCE Junlin Wang wangjunlin572@163.com

RECEIVED 22 April 2023 ACCEPTED 07 August 2023 PUBLISHED 21 August 2023

CITATION

Wu X, Gu H and Wang J (2023) Impact of hypertensive disorders of pregnancy on maternal and neonatal outcomes of twin gestation: a systematic review and meta-analysis. Front. Pediatr. 11:1210569. doi: 10.3389/fped.2023.1210569

COPYRIGHT

© 2023 Wu, Gu and Wang. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Impact of hypertensive disorders of pregnancy on maternal and neonatal outcomes of twin gestation: a systematic review and meta-analysis

Xiaoqing Wu¹, Huifeng Gu² and Junlin Wang^{3*}

¹Intensive Care Unit, Huzhou Maternity & Child Health Care Hospital, Huzhou, China, ²Nursing Department, Huzhou Maternity & Child Health Care Hospital, Huzhou, China, ³Obstetrical Department, Huzhou Maternity & Child Health Care Hospital, Huzhou, China

Background: The impact of hypertensive disorders of pregnancy (HDP) on outcomes of twin gestations is not clear. We aimed to collate data via this meta-analysis to examine how HDP alters maternal and neonatal outcomes of twin gestations.

Methods: Studies comparing pregnancy outcomes of twin gestations based on HDP and published on the databases of PubMed, CENTRAL, Scopus, Web of Science, and Embase between 1 January 2000 to 20 March 2023 were eligible for inclusion.

Results: Twelve studies were included. A cumulative of 355,129 twin gestations were analyzed in the current meta-analysis. The pooled analysis found that the presence of HDP increases the risk of preterm birth (OR: 1.86 95% CI: 1.36, 2.55 $I^2 = 99\%$) and cesarean section in twin gestations (OR: 1.36 95% CI: 1.20, 1.54 $I^2 = 89\%$). Meta-analysis showed a significantly increased risk of low birth weight (OR: 1.30 95% CI: 1.10, 1.55 $I^2 = 97\%$), small for gestational age (OR: 1.30 95% CI: 1.09, 1.55 $I^2 = 96\%$) and neonatal intensive care unit admissions (OR: 1.77 95% CI: 1.43, 2.20 $I^2 = 76\%$) with HDP in twin gestations. There was no difference in the incidence of 5-min Apgar scores <7 (OR: 1.07 95% CI: 0.87, 1.38 $I^2 = 79\%$) but a lower risk of neonatal death (OR: 0.39 95% CI: 0.25, 0.61 $I^2 = 62\%$) with HDP.

Conclusion: HDP increases the risk of preterm birth, cesarean sections, low birth weight, SGA, and NICU admission in twin gestations. Contrastingly, the risk of neonatal death is reduced with HDP. Further studies are needed to corroborate the current results.

Systematic Review Registration: PROSPERO (CRD42023407725).

KEYWORDS

twin pregnancy, hypertension, preeclampsia, neonatal, maternal

Introduction

The use of assisted reproductive technology has metamorphosed the management of infertility in recent times (1). However, as a corollary, there has been an upward trend in the incidence of twin and multiple pregnancies worldwide (2). Research has documented that twin gestations have significantly inferior outcomes as compared to singleton pregnancies (3). Mothers with twin gestation have a higher risk of gestational diabetes and hypertensive disorders of pregnancy (HDP) while their infants have an increased risk of fetal growth restriction and neonatal death (3).

HDP along with gestational hypertension and preeclampsia are among the most common causes of adverse maternal and neonatal outcomes in pregnancy. HDP is known to escalate the risk of cesarean section, preterm birth, low birth weight, small for gestational age (SGA), neonatal admission, and neonatal death in singleton pregnancies (4). Given that about 10% of pregnancies around the world are affected by HDP, the burden of adverse events is indeed huge (5). Moreover, the risk of HDP increases proportionately with multiple gestations and is as high as nearly 20% for twin gestations (6, 7). Such increased risk has been primarily associated with higher placental mass causing increased circulating levels of the anti-angiogenic molecule sFlt1 in twin gestations, which is postulated in the pathophysiology of the disease (8).

Despite the high prevalence of HDP and increasing rates of twin gestations, the impact of HDP on the outcomes of twin pregnancies is still unclear. Are the risk of adverse maternal and neonatal outcomes similar to those of singleton pregnancies or does HDP further heighten the occurrence of deleterious events? Literature comparing pregnancy outcomes of twin gestations with and without HDP is scarce and conflicting (9–11). To date, no study has comprehensively consolidated the available data to present clarity on the effects of HDP in twin pregnancies. To overcome this deficiency in literature, the present review was designed to assess the impact of HDP on maternal and neonatal outcomes of twin gestations.

Material and methods

Search details

The review protocol was registered on PROSPERO (CRD42023407725) and the PRISMA statement reporting guidelines were followed (12). Two reviewers conducted the literature search separately. The databases included PubMed, CENTRAL, Scopus, Web of Science, and Embase. Google Scholar was searched separately for gray literature. All articles available online between 1 January 2000 to 20 March 2023 were eligible for inclusion. There was no restriction on the language of publication.

We combined free-text and MeSH keywords with Boolean operators (AND/OR) for the literature search. The search terms included "hypertensive disorders of pregnancy", "gestational hypertension", "preeclampsia", "eclampsia", "twin", "pregnancy", and "gestation". The PubMed search strategy is presented in detail in **Supplementary Table S1**. Similar search threads were used for all other databases.

The search results were de-duplicated and the remaining records were carefully screened based on the eligibility criteria. Non-relevant studies were excluded based on title/abstract screening. The remaining studies underwent full-text analysis for inclusion in the review. Any disagreements were solved by consensus. The references list of eligible articles was hand searched for additional articles.

Inclusion criteria

Based on the PECOS, the inclusion criteria were: (1) Population: women with twin pregnancies, (2) Exposure: diagnosis of HDP (3) Comparison: No HDP 4: Outcomes: Any maternal and neonatal pregnancy outcomes. We quantitatively analyzed an outcome if data was reported by at least three studies.

HDP was defined as a diagnosis of either gestational hypertension, preeclampsia, or eclampsia. Gestational hypertension was defined as new-onset hypertension recorded on two occasions after 20 weeks of gestation. Preeclampsia was defined as gestational hypertension with a new onset of proteinuria, or involvement of one of the systemic organ systems. Eclampsia was defined as hypertension with proteinuria with generalized seizures or coma and could include pathologic edema. Outcomes were not pre-defined per-se and all definitions by the included studies were acceptable.

Studies comparing outcomes with singleton pregnancies, not reporting any maternal or neonatal adverse outcome, those with duplicate/overlapping data, reviews and editorials were excluded. If two or more articles used the same dataset from the same period, the study with the highest number of patients was included.

Data management and study quality

Data on the author's last name, year of publication, location, study type, and outcomes were extracted. Also, the reviewers gathered data on the following maternal characteristics: mode of conception, HDP type, sample size, age, primiparity, smokers, obesity, gestational diabetes, and chorionicity. Two reviewers were independently involved in data collection. For maternal outcomes, sufficient data were available for pre-term birth (<37 weeks) and risk of cesarean section. For neonatal outcomes, meta-analysis was conducted for low birth weight (<2,500 g), SGA (<10th percentile), 5-min Apgar score <7, neonatal death, and neonatal intensive care unit (NICU) admission.

Two authors judged the study's quality based on Newcastle Ottawa Scale (NOS) (13). The NOS has three domains: representativeness of the study cohort, comparability, and measurement of outcomes. Points are given depending on the NOS questions. The final score of a study can range from 0 to 9.

Statistical analysis

Statistical analysis was done using "Review Manager" [RevMan, version 5.3; Nordic Cochrane Centre (Cochrane Collaboration), Copenhagen, Denmark; 2014]. Crude dichotomous data on outcomes were sourced from studies and combined to generate an odds ratio (OR) with 95% confidence intervals (CI) in a random-effects model. The I^2 statistic was the tool to determine inter-study heterogeneity. $I^2 < 50\%$ meant low and >50% meant substantial heterogeneity.

Results

On completing the literature search and deduplication of data, a total of 3,692 articles were found (**Figure 1**). The reviewers examined these articles for primary eligibility and 3,668 were excluded due to non-relevance. The 24 studies which were selected for full-text analysis underwent detailed examination and 12 were found to be appropriate based on the inclusion criteria (9, 10, 21, 22, 11, 14–20). The remaining 12 studies were excluded for reasons mentioned in **Figure 1**.

All articles were published between 2012 and 2022. Six of the studies (9, 10, 16, 17, 20, 21) were from North America (USA or Canada) (Table 1). The remaining were from Slovenia (15), Italy (11), the UK (22), Ireland (18), and China (19). One study (9) included only assisted reproductive technology-based gestations, while all others (10, 11, 22, 14–21) included natural conception as well. Seven studies (9, 10, 16, 18, 20–22) included twin pregnancies with gestational hypertension and preeclampsia. Three studies (11, 14, 17) included only gestational hypertension

and two (15, 19) included only preeclampsia. A cumulative of 355,129 twin gestations were analyzed in the included cohorts. The mean age of the females was \leq 36 in all studies. The majority of studies did not report data on the prevalence of smokers, obesity, and gestational diabetes in their cohorts. Two studies (10, 21) included only dichorionic twin gestations while others included both monochorionic and dichorionic twins. The studies received a NOS score of 6 to 8.

Six studies (9, 11, 14, 17, 19, 20) reported data on preterm birth. The pooled analysis found that the presence of HDP increases the risk of preterm birth in twin gestations (OR: 1.86 95% CI: 1.36, 2.55 $I^2 = 99\%$) (Figure 2). Similarly, the risk of cesarean section was also significantly increased with the presence of HDP in twin gestations (OR: 1.36 95% CI: 1.20, 1.54 $I^2 = 89\%$) (Figure 2).

Five studies (9, 14, 15, 17, 19) reported data on the incidence of low birth weight. Meta-analysis showed a significantly increased risk of low birth weight in twin gestations with HDP (OR: 1.30 95% CI: 1.10, 1.55 $I^2 = 97\%$) (Figure 3). Data on the incidence of



Frontiers in Pediatrics

TABLE 1 Details of included studies.

NOS score	œ	8		×		8	8	×		×		6		9		×		6	9		
Chorionicity	NR	NR		Mixed		Mixed	Dichorionic	Mixed		Dichorionic		Mixed		NR		NR		Mixed	Mixed		
Gestational diabetes (%)	NR	14.7	10	8.5	7.7	NR	NR	NR		NR		NR		NR		NR		NR	6.6	3.1	
Obese (%)	15.8 12.3	26.8	17.3	24.8	74.1	NR	NR	NR		NR		NR		NR		NR		8.3	NR		
Smoker (%)	0.3 0.4	6.1	8.5	NR		5.2	NR	NR		NR		NR		NR		7.5	10.8	NR	9.4	9.2	
Primaparous (%)	38.4 33.7	60.9	41.3	54.4	39.4	NR	62.7	6.69	68.9	72.1	62	NR		60.1	57.3	59.6	39.7	61.8	NR		
Age	35.6 35	32.7	32	NR		33	34.1	29	29	34.7	34.2	NR		31	31	NR		34.1	30	30	
Sample size	10,817 41.903	2,120	12,556	270	1,296	1,473	1,520	143	367	136	321	92	885	196	912	22,839	2,55,982	578	181	542	
Groups	HDP No HDP	HDP	No HDP	HDP	No HDP	Total sample	Total sample	HDP	No HDP	HDP	No HDP	HDP	No HDP	HDP	No HDP	HDP	No HDP	Total sample	HDP	No HDP	
HDP type	GH, PE	GH, PE		GH		GH, PE	GH, PE	PE		GH, PE		GH, PE		GH		GH		GH, PE	PE		
Conception	ART	Mixed		Mixed		Mixed	Mixed	Mixed		Mixed		Mixed		Mixed		Mixed		Mixed	Mixed		
Location	USA	Canada		Ireland		UK	Canada	China		USA		Ireland		Italy		USA		USA	Slovenia		
Study	Liu et al. (9)	Aviram et al. (20)		Hayes-Ryan et al. (14)		Giorgione et al. (22)	Proctor et al. (21)	Yuan et al. (19)		Sparks et al. (10)		Hehir et al. (18)		Ferrazzani et al. (11)		Luo et al. (17)		Fox et al. (16)	Lučovnik et al. (15)		

ART, assisted reproductive technology; GH, gestational hypertension; PE, Preeclampsia; NR, not reported; HDP, hypertensive disorders of pregnancy.

	HDP		Cont	trol		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
1.1.1 Pre-term birth	(<37 we	eks)						
Luo 2014	14703	22839	141380	255982	18.3%	1.46 [1.42, 1.51]	2014	
Ferrazzani 2016	114	196	516	912	15.5%	1.07 [0.78, 1.46]	2016	· +
Yuan 2016	117	143	252	367	12.9%	2.05 [1.27, 3.31]	2016	
Hayes-Ryan 2020	388	540	1373	2592	17.0%	2.27 [1.85, 2.78]	2020	
Aviram 2021	1432	2120	6328	12556	18.0%	2.05 [1.86, 2.26]	2021	
Liu 2022	8200	10817	22614	41903	18.2%	2.67 [2.55, 2.80]	2022	•
Subtotal (95% CI)		36655		314312	100.0%	1.86 [1.36, 2.55]		•
Total events	24954		172463					
Heterogeneity: Tau ² =	= 0.14; Cł	ni ² = 477	7.15, df =	5 (P < 0.0	00001); I ²	= 99%		
Test for overall effect	: Z = 3.85	5 (P = 0.0)	0001)					
1.1.2 C-section								
Lucovnik 2012	105	181	272	542	8.3%	1.37 [0.98, 1.93]	2012	
Luo 2014	8744	22839	83486	255982	20.3%	1.28 [1.25, 1.32]	2014	•
Ferrazzani 2016	129	196	614	912	8.7%	0.93 [0.67, 1.29]	2016	· +
Hehir 2016	69	92	564	885	5.0%	1.71 [1.04, 2.79]	2016	·
Yuan 2016	102	143	249	367	6.3%	1.18 [0.77, 1.80]	2016	· +
Hayes-Ryan 2020	385	540	1707	2592	13.4%	1.29 [1.05, 1.58]	2020	• -
Aviram 2021	1450	2120	7527	12556	18.3%	1.45 [1.31, 1.60]	2021	
Liu 2022	9263	10817	32860	41903	19.6%	1.64 [1.55, 1.74]	2022	
Subtotal (95% CI)		36928		315739	100.0%	1.36 [1.20, 1.54]		♦
Total events	20247		127279					
Heterogeneity: Tau ² =	= 0.02; Cł	ni² = 63.	93, df = 7	7 (P < 0.00	0001); I ² :	= 89%		
Test for overall effect	: Z = 4.73	3 (P < 0.0	00001)					
								Favours [HDP] Favours [control]

Meta-analysis of preterm birth and cesarean section with and without HDP in twin gestations.



SGA was reported by nine studies (9–11, 16, 17, 19–22). On pooled analysis, a significantly high risk of SGA was seen with HDP in twin gestations (OR: 1.30 95% CI: 1.09, 1.55 I^2 = 96%) (Figure 3).

Five studies (9, 14, 17, 19, 20) reported data on Apgar scores. Meta-analysis showed no difference in the incidence of 5-min Apgar scores <7 in the two groups (OR: 1.07 95% CI: 0.87, 1.38



 I^2 = 79%) (Figure 4). Also, meta-analysis showed an increased risk of NICU admissions with HDP in twin gestations (OR: 1.77 95% CI: 1.43, 2.20 I^2 = 76%) but a lower risk of neonatal death (OR: 0.39 95% CI: 0.25, 0.61 I^2 = 62%) (Figure 4).

Discussion

After combining data from 12 studies (9, 10, 21, 22, 11, 14–20), we noted that HDP has a mixed effect on pregnancy outcomes of twin pregnancies. For maternal outcomes, the presence of HDP increased the risk of preterm birth and cesarean sections. However, for neonatal outcomes, HDP reduced the risk of neonatal death while increasing the risk of low birth weight, SGA, and NICU admission.

HDP continues to be a major comorbidity affecting women during gestation. Research from several regions has confirmed the fact that the risk of HDP increases significantly in twin gestations. The CoNARTaS study from Scandinavian countries conducted between 1988 and 2007 has shown that the risk of HDP is two-fold with twin gestations and assisted reproductive technology has little impact on the incidence of HDP (23). Another study by Laine et al. (24) has found the risk of preeclampsia to be three to four times with twin gestations which is independent of maternal age, parity, educational level, smoking, comorbidities, and use of in-vitro fertilization. Similarly, another Australian study has also noted a twofold elevated risk of both gestational hypertension and preeclampsia among twins vs. singleton pregnancies (25). Despite such confirmatory research, the reason behind an increased risk of HDP remains unclear. Women with twin gestations have significantly higher weight gain compared to singleton pregnancies which in turn increases cardiac output and further increases blood pressure (26, 27). Furthermore, since the definition of HDP is the same for both singleton and twins, this directly increases the absolute incidence of HDP with twin gestations (9). Molecular experiments have shown that alteration of placental mass causing increased circulating levels of the anti-angiogenic molecule sFlt1 is an important factor behind the high risk (8). Recently, Springer et al. (28) have implicated neutrophil gelatinase-associated lipocalin as an important factor causing HDP in twin gestations. Indeed, only further research can demonstrate the pathophysiology of the increased risk of HDP in twin gestations.

The deleterious impact of HDP on maternal and neonatal outcomes is well-documented. In a recent all-encompassing meta-analysis of 152 cohort studies with 36,374,542 mothers, Li et al. (29) showed that HDP significantly increases the risk of perinatal and neonatal death, congenital malformations, fetal

growth restrictions, SGA, and low birth weight. While their review also included a subgroup on twin gestations, the maximum number of studies on twin gestations was only three. Zhang et al. (30) in another review have demonstrated a significantly increased risk of congenital heart defects in neonates based on the mother's history of HDP. Bramham et al. (4) have also shown a higher risk of preterm delivery and cesarean sections in mothers with HDP. The current study, which is the first to comprehensively assess maternal and neonatal outcomes of twin gestations with and without HDP, conforms to the findings of these prior reviews. Important to note that the outcomes of our review were restricted by the data reported in the limited number of included studies and hence all relevant outcomes could not be quantitatively assessed. We found that HDP increased the risk of preterm birth and cesarean sections in mothers with twin gestations. The high rates of cesarean sections could be attributed to tendency to perform cesarean sections for mothers with preeclampsia. Studies have reported that up to 85% of women with preeclampsia deliver by cesarean section to reduce the incidence of maternal and neonatal complications (31, 32). For neonatal outcomes, HDP was found to increase the risk of low birth weight, SGA, and NICU admission but did not influence Apgar <7 scores. Recently, Wang et al. (33) have also shown that HDP increases the risk of SGA in twin gestations. However, their review was restricted to only SGA, and only seven studies were included.

An important finding of this review was the protective effect of HDP on neonatal mortality as HDP was found to reduce the risk of neonatal death by 61%. On scrutiny of the forest plot, it was noted that the outcomes were primarily influenced by two large American studies by Luo et al. (17) and Liu et al. (9). Both these administrative database studies from the USA noted a statistically significant reduction of neonatal mortality with HDP in twin pregnancies. Nevertheless, the cause of such an effect is still unknown. Luo et al. (17) speculated that antihypertensive medications may benefit fetal survival as drugs like labetalol may promote fetal lung maturation and lower mortality. Another possibility put forward was that the other unreported and serious maternal comorbidities or fetal complications could have been higher in the non-HDP group which increased neonatal mortality. Lastly, it is plausible that these results could be due to selection bias. Women with HDP could have received better ante-natal care in anticipation of complications which could have affected neonatal mortality rates. Nevertheless, further prospective studies from other countries are needed to clarify if the protective effect is real or a statistical artifact due to unmeasured confounding.

Our review was unable to examine the role of chorionicity as a confounder influencing outcomes of twin gestations affected by HDP. While a few studies focused only on dichorionic gestations the others included a mixed population of monochorionic and dichorionic pregnancies. The scarce data prevented a subgroup or a meta-regression analysis. However, Che et al. (34) have shown that outcomes of twin gestations complicated by HDP differ based on chorionicity. In dichorionic pregnancies, adverse pregnancy outcomes increase with higher grades of HDP while no such effect was noted in monochorionic twins.

There are a few limitations to our review. Firstly, the outcomes were derived from retrospective data and a small number of studies. Retrospective data is prone to bias which could affect the outcome of the systematic review. However, it is important to note that randomized controlled trials are not possible as the exposure (HDP) is a medical complication which cannot be induced. Also, the number of studies in each meta-analysis was <10. Inaccuracies in data entry could have altered the outcomes. Secondly, the two (9, 17) database studies from the USA were shown to influence outcomes due to their significantly huge sample size. Thirdly, the significant heterogeneity in the analysis is also a cause of concern. Variations in study populations, method of conception, comorbidities, obesity, gestational diabetes, chorionicity, etc. could all have influenced the outcomes and increased inter-study heterogeneity. Also, only crude outcome data were pooled in the review due to a lack of reporting of adjusted data amongst the included studies. Fourthly, studies did not report data on anti-hypertensive treatments which made it unfeasible to assess how these drugs affected pregnancy outcomes. Lastly, the scarce data made it impossible to assess the impact of assisted reproductive technology and chorionicity on outcomes.

Conclusions

Available evidence suggests that HDP increases the risk of preterm birth, cesarean sections, low birth weight, SGA, and NICU admission in twin gestations. Contrastingly, the risk of neonatal death is reduced with HDP. Further studies are needed to corroborate the current results.

Data availability statement

Publicly available datasets were analyzed in this study. This data can be found here: The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work, and approved it for publication.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their

affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Kushnir VA, Barad DH, Albertini DF, Darmon SK, Gleicher N. Systematic review of worldwide trends in assisted reproductive technology 2004–2013. *Reprod Biol Endocrinol.* (2017) 15:1–9. doi: 10.1186/S12958-016-0225-2/FIGURES/3

2. Sunderam S, Kissin DM, Zhang Y, Jewett A, Boulet SL, Warner L, et al. Assisted reproductive technology surveillance—United States, 2017. *MMWR Surveill Summ.* (2020) 69:1–24. doi: 10.15585/MMWR.SS6909A1

3. Meyer R, Orvieto R, Israel A, Mohr-Sasson A, Timerman Y, Gorodesky T, et al. Outcomes of singleton versus twin pregnancies in the fifth and sixth decades. *Eur J Obstet Gynecol Reprod Biol.* (2018) 231:255–61. doi: 10.1016/J.EJOGRB.2018.11.007

4. Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC. Chronic hypertension and pregnancy outcomes: systematic review and metaanalysis. *Br Med J.* (2014) 348:g2301. doi: 10.1136/BMJ.G2301

5. Sutton ALM, Harper LM, Tita ATN. Hypertensive disorders in pregnancy. Obstet Gynecol Clin North Am. (2018) 45:333–47. doi: 10.1016/J.OGC.2018.01.012

 Bartnik P, Kosinska-Kaczynska K, Kacperczyk J, Ananicz W, Sierocińska A, Wielgos M, et al. Twin chorionicity and the risk of hypertensive disorders: gestational hypertension and Pre-eclampsia. *Twin Res Hum Genet.* (2016) 19:377–82. doi: 10.1017/THG.2016.17

7. Narang K, Szymanski LM. Multiple gestations and hypertensive disorders of pregnancy: what do we know? *Curr Hypertens Rep.* (2020) 23:1. doi: 10.1007/S11906-020-01107-4

8. Bdolah Y, Lam C, Rajakumar A, Shivalingappa V, Mutter W, Sachs BP, et al. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? *Am J Obstet Gynecol.* (2008) 198:428.e1–e6. doi: 10.1016/J.AJOG.2007.10.783

9. Liu T, Gao R, Liu Y, Zhao K, Su X, Wong HC, et al. Hypertensive disorders of pregnancy and neonatal outcomes in twin vs. singleton pregnancies after assisted reproductive technology. *Front Pediatr.* (2022) 10:839882. doi: 10.3389/FPED.2022.839882

10. Sparks TN, Nakagawa S, Gonzalez JM. Hypertension in dichorionic twin gestations: how is birthweight affected? J Matern Fetal Neonatal Med. (2017) 30:380-5. doi: 10.3109/14767058.2016.1174209

11. Ferrazzani S, Moresi S, De Feo E, Degennaro VA, Salvi S, Boccia S, et al. Is gestational hypertension beneficial in twin pregnancies? *Pregnancy Hypertens*. (2015) 5:171-6. doi: 10.1016/J.PREGHY.2015.01.003

12. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Int J Surg.* (2021) 88:105906. doi: 10.1016/j.ijsu.2021.105906

13. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/ oxford.asp (Accessed October 30, 2020).

14. Hayes-Ryan D, Meaney S, Hodnett A, Geisler M, O'Donoghue K. The maternal and perinatal implications of hypertensive disorders of pregnancy in a multiple pregnancy cohort. *Acta Obstet Gynecol Scand.* (2020) 99:525–36. doi: 10.1111/AOGS.13774

15. Lučovnik M, Tul N, Verdenik I, Novak Ž, Blickstein I. Risk factors for preeclampsia in twin pregnancies: a population-based matched case-control study. *J Perinat Med.* (2012) 40:379–82. doi: 10.1515/JPM-2011-0252

16. Fox NS, Saltzman DH, Oppal S, Klauser CK, Gupta S, Rebarber A. The relationship between preeclampsia and intrauterine growth restriction in twin pregnancies. *Am J Obstet Gynecol.* (2014) 211:422.e1–e5. doi: 10.1016/J.AJOG.2014. 05.035

17. Luo QG, Zhang JY, Cheng WW, Audibert F, Luo ZC. Is gestational hypertension protective against perinatal mortality in twin pregnancies? *PLoS One.* (2014) 9:e94865. doi: 10.1371/JOURNAL.PONE.0094865

18. Hehir MP, Breathnach FM, McAuliffe FM, Geary MP, Daly S, Higgins J, et al. Gestational hypertensive disease in twin pregnancy: influence on outcomes in a

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2023. 1210569/full#supplementary-material

large national prospective cohort. Aust N Z J Obstet Gynaecol. (2016) 56:466-70. doi: 10.1111/AJO.12483

19. Yuan T, Wang W, Li XL, Li CF, Li C, Gou WL, et al. Clinical characteristics of fetal and neonatal outcomes in twin pregnancy with preeclampsia in a retrospective case-control study: a STROBE-compliant article. *Medicine (Baltimore)*. (2016) 95: e5199. doi: 10.1097/MD.00000000005199

20. Aviram A, Berger H, Abdulaziz KE, Barrett JFR, Murray-Davis B, McDonald SD, et al. Outcomes associated with hypertensive disorders of pregnancy in twin compared with singleton gestations. *Obstet Gynecol.* (2021) 138:449–58. doi: 10.1097/AOG. 00000000004506

21. Proctor LK, Kfouri J, Hiersch L, Aviram A, Zaltz A, Kingdom J, et al. Association between hypertensive disorders and fetal growth restriction in twin compared with singleton gestations. *Am J Obstet Gynecol.* (2019) 221:251.e1–e8. doi: 10.1016/J. AJOG.2019.04.022

22. Giorgione V, Bhide A, Bhate R, Reed K, Khalil A. Are twin pregnancies complicated by weight discordance or fetal growth restriction at higher risk of preeclampsia? *J Clin Med.* (2020) 9:1–10. doi: 10.3390/JCM9103276

23. Opdahl S, Henningsen AA, Tiitinen A, Bergh C, Pinborg A, Romundstad PR, et al. Risk of hypertensive disorders in pregnancies following assisted reproductive technology: a cohort study from the CoNARTaS group. *Hum Reprod.* (2015) 30:1724–31. doi: 10.1093/HUMREP/DEV090

24. Laine K, Murzakanova G, Sole KB, Pay AD, Heradstveit S, Raïsänen S. Prevalence and risk of pre-eclampsia and gestational hypertension in twin pregnancies: a population-based register study. *BMJ Open.* (2019) 9:e029908. doi: 10.1136/BMJOPEN-2019-029908

25. Wang YA, Chughtai AA, Farquhar CM, Pollock W, Lui K, Sullivan EA. Increased incidence of gestational hypertension and preeclampsia after assisted reproductive technology treatment. *Fertil Steril.* (2016) 105:920–6.e2. doi: 10.1016/J. FERTNSTERT.2015.12.024

26. Iwama N, Metoki H, Nishigori H, Mizuno S, Takahashi F, Tanaka K, et al. Blood pressure changes during twin pregnancies: the Japan environment and children's study. J Hypertens. (2019) 37:206–15. doi: 10.1097/HJH.00000000001846

27. Kuleva M, Youssef A, Maroni E, Contro E, Pilu G, Rizzo N, et al. Maternal cardiac function in normal twin pregnancy: a longitudinal study. *Ultrasound Obstet Gynecol.* (2011) 38:575–80. doi: 10.1002/UOG.8936

28. Springer S, Franz M, Worda K, Gorczyca ME, Haslinger P, Worda C. Neutrophil gelatinase-associated lipocalin and hypertensive disorders of pregnancy: a cohort study in twin pregnancies. *J Clin Med.* (2022) 11:4163. doi: 10.3390/JCM11144163

29. Li F, Wang T, Chen L, Zhang S, Chen L, Qin J. Adverse pregnancy outcomes among mothers with hypertensive disorders in pregnancy: a meta-analysis of cohort studies. *Pregnancy Hypertens*. (2021) 24:107–17. doi: 10.1016/J.PREGHY.2021.03.001

30. Zhang S, Qiu X, Wang T, Chen L, Li J, Diao J, et al. Hypertensive disorders in pregnancy are associated with congenital heart defects in offspring: a systematic review and meta-analysis. *Front Cardiovasc Med.* (2022) 9:842878. doi: 10.3389/FCVM.2022. 842878

31. Wu SW, Zhang WY. Effects of modes and timings of delivery on feto-maternal outcomes in women with severe preeclampsia: a multi-center survey in mainland China. *Int J Gen Med.* (2021) 14:9681–7. doi: 10.2147/IJGM.S335893

32. Amorim MMR, Katz L, Barros AS, Almeida TSF, Souza ASR, Faúndes A. Maternal outcomes according to mode of delivery in women with severe preeclampsia: a cohort study. J Matern Fetal Neonatal Med. (2015) 28:654–60. doi: 10.3109/14767058.2014.928689

33. Wang M, Wang X, Chen Z, Zhang F. Gestational hypertensive disease and small for gestational age infants in twin pregnancy: a systematic review and meta-analysis. *J Obstet Gynaecol Res.* (2022) 48:2677–85. doi: 10.1111/JOG.15401

34. Che R, Pei J, Chen H, Dong L, Wu Y, Hua X. The influence of hypertensive disorders during pregnancy on the perinatal outcome of different chorionic twins. *J Matern Fetal Neonatal Med.* (2022) 35:7146–52. doi: 10.1080/14767058.2021. 1945574